Company intelligence / Profile preview

Medovex

Tampa, Florida, United States

Ownership: Private
Development stage: Other

Overview

Medovex develops the DenerveX System, a minimally invasive device for long-lasting relief from facet joint pain, with regulatory approval in the UK as of January 2025. Over 1,500 patients treated; also manages Lung Health Institute for regenerative therapies in lung diseases.

Therapeutic areas: NeurologyPulmonologyRheumatology
Modalities: Device
Industry: Biotech

Beyond the preview

Go deeper on Medovex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medovex.

Explore the full profile